Australia's Neuren jumps as EU committee backs key drug authorisation
BUZZ-Australia's Neuren jumps as EU committee backs key drug authorisation ** Shares of Neuren Pharmaceuticals NEU.AX advance as much as 31.4% to A$16.03, their biggest intraday pct gain in over two and a half years
** Stock leads gains across both the benchmark ASX200 .AXJO and its healthcare subindex .AXHJ, which are up 0.4% and 0.6% respectively
** Biopharma firm says that a committee has issued a positive opinion backing EU marketing authorisation for Daybu
** Should approval and launch follow, NEU stands poised to secure a $35 million EU milestone on first sale, alongside royalties and potential sales-based uplifts - Co
** NEU adds, if approved by the European Commission, Daybu would mark the EU’s first authorised therapy targeting the neurobehavioural symptoms of Rett syndrome
** Stock down 16.4% YTD
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com; X: @thatstanishk http://www.x.com/thatstanishk;))
Recent news on Neuren Pharmaceuticals
See all newsStrong partner sales propel Neuren Pharmaceuticals to top of Australia benchmark
Brief: Neuren Pharmaceuticals Says DAYBU Recommended For Approval In European Union
Australia's Neuren jumps as EU committee backs key drug authorisation
Brief: Neuren Pharmaceuticals Reassessing Capital Management Options
Brief: Neuren Pharmaceuticals Says Daybue Stix Now Broadly Available In US For Rett Syndrome